Key Highlights

• Jupiter Neurosciences, Inc. Has announced the appointment of Dr. Tomas J. Philipson to its Board of Directors, effective June 26, 2026.

• Philipson, age 64, will also serve on the Board's Audit and Compensation Committees.

• He is set to receive an option to purchase 90,000 shares of common stock as a sign‑on incentive, with additional options for 446,428 shares tied to annual director compensation.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has announced a new addition to its governing body by naming Tomas J. Philipson, Ph.D. As a member of the Board of Directors. The appointment takes effect promptly, positioning Philipson to lend strategic insight as the company continues to evolve within the dynamic health‑care environment.

Under the company’s bylaws, his service will persist until a successor is selected at the forthcoming annual shareholder gathering, consistent with standard practice for directors.

New Board Member Profile

Dr. Philipson arrives with a deep background in health‑care economics, having spent many years in both academic settings and public‑policy roles before turning to private‑sector consulting. Beginning in the middle of 2020, he founded and runs a consultancy that advises biopharmaceutical firms and health‑care organizations on economic analysis, pricing strategy, and regulatory policy.

This blend of scholarly rigor and practical advisory work equips him to address the complex market forces that influence Jupiter’s therapeutic pipeline and commercial pathways.

Committee Roles Defined

In addition to his board seat, Philipson has been assigned to the Audit Committee and the Compensation Committee. These assignments enable him to directly oversee financial reporting integrity and to shape executive remuneration frameworks, both of which are critical to sustaining investor confidence and aligning incentives across the organization. His expertise in fiscal oversight is expected to reinforce the company’s governance standards as it advances clinical development programs.

Equity Compensation Structure

As part of the compensation arrangement for his director duties, Dr. Philipson will receive equity‑based awards rather than the typical cash retainer. The initial grant consists of a sign‑on option covering 90,000 shares of Jupiter’s common stock, with an exercise price set according to the market price prevailing in late June 2026.

This award will vest in equal quarterly portions over a three‑year horizon, conditional upon his continued participation on the board.

Additional Stock Options

Complementing the sign‑on grant, the compensation plan includes a further option representing 446,428 shares of common stock. This larger pool is structured to replace the usual cash compensation that directors receive, and it will also vest over a 36‑month period under comparable service conditions. The dual‑option framework reflects Jupiter’s strategy of tying leadership rewards closely to shareholder value creation.

Notable Past Roles

Philipson’s public‑service résumé features a stint as the acting head of the White House Council of Economic Advisers, where he contributed to macro‑economic policy formulation. He has also engaged with regulatory agencies such as the Food and Drug Administration and the Centers for Medicare & Medicaid Services in advisory capacities. These experiences provide him with insight into the policy landscape that shapes drug development, pricing, and reimbursement.

Educational Credentials

Dr. Philipson earned a bachelor's degree in mathematics from Uppsala University and advanced graduate degrees in economics from the Wharton School at the University of Pennsylvania. His academic training underpins his analytical approach to health‑care economics, including cost‑effectiveness evaluation and market access strategy.

Ongoing Advisory Involvements

Outside of his board responsibilities, Philipson maintains advisory relationships with several venture and technology firms, including MEDA Ventures, where he offers guidance on health‑care market dynamics. These connections allow him to stay abreast of emerging innovations and to foster collaborative opportunities that could benefit Jupiter’s research and development initiatives. Overall, the addition of Dr.

Philipson to the board brings a combination of policy acumen, economic expertise, and industry network that aligns with Jupiter Neurosciences’ goal of delivering novel neurological therapies while navigating the regulatory and financial complexities of the biotech sector.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.